Compare BHRB & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHRB | TSHA |
|---|---|---|
| Founded | 1852 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2023 | 2020 |
| Metric | BHRB | TSHA |
|---|---|---|
| Price | $70.92 | $4.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $79.75 | $13.00 |
| AVG Volume (30 Days) | 111.7K | ★ 3.5M |
| Earning Date | 10-22-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | ★ 173.76 | 5.56 |
| EPS | ★ 4.03 | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | $26.58 | N/A |
| Revenue Next Year | $11.36 | $1,023.00 |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $59.00 | $3.46 |
| 52 Week High | $75.09 | $7.30 |
| Indicator | BHRB | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 48.66 |
| Support Level | $70.58 | $3.92 |
| Resistance Level | $72.62 | $4.59 |
| Average True Range (ATR) | 1.91 | 0.26 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 49.72 | 62.58 |
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.